SCHEMBL3765840

SCHEMBL3765840

CCOc1cccc(-c2ccc(N3CCN(CC(=O)N4CCN(C5CCC5)CC4)CC3)nn2)c1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.45
THRB P10828 1/20 0.45
NPC1 O15118 8/20 0.43
RAB9A P51151 8/20 0.43
HRH3 Q9Y5N1 2/20 0.41
ALDH1A1 P00352 3/20 0.41
HTT P42858 2/20 0.41
MAPT P10636 1/20 0.41
MAPK1 P28482 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
KDM4E B2RXH2 1/20 0.40
ACHE P22303 1/20 0.40
GAA P10253 1/20 0.40
LMNA P02545 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C19 P33261 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3767549 0.92 MAPK1 (0.50) TP53NPC1RAB9AHRH3ALDH1A1
SCHEMBL3774008 0.90 HRH3 (0.41) NPC1RAB9AHRH3ALDH1A1HTT
SCHEMBL3763141 0.90 ALDH1A1 (0.48) TP53THRBNPC1RAB9AHRH3
SCHEMBL3775894 0.89 HRH3 (0.45) NPC1RAB9AHRH3ALDH1A1HTT
SCHEMBL3767554 0.88 HTT (0.41) HRH3ALDH1A1HTTMAPTMAPK1
SCHEMBL3768006 0.88 NPC1 (0.42) TP53NPC1RAB9AHRH3ALDH1A1
SCHEMBL5555542 0.88 PANK3 (0.43) NPC1RAB9AHRH3ALDH1A1HTT
SCHEMBL3765532 0.87 NPC1 (0.44) TP53NPC1RAB9AHRH3ALDH1A1
SCHEMBL3771707 0.87 GRM5 (0.46) TP53NPC1RAB9AHRH3HTT
SCHEMBL3769164 0.86 TP53 (0.45) TP53NPC1RAB9AHRH3HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 TP53 3661/4885THRB 603/4885NPC1 3462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.